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ABSTRACT 
Astroblastomas are rare brain tumours which predominate in children and young 
adults, and have a controversial claim as a distinct entity, with no established WHO 
grade. Reports suggest a better outcome than high grade gliomas, though they 
frequently recur. Recently, they have been described to overlap with a newly-
discovered group of tumours described as ’high grade neuroepithelial tumour with 
MN1 alteration’ (CNS HGNET-MN1), defined by global methylation patterns and 
strongly associated with gene fusions targeting MN1. We have studied a unique case 
of astroblastoma arising in a 6 year-old girl, with multiple recurrences over a period of 
10 years, with the pathognomonic MN1:BEND2 fusion. Exome sequencing allowed 
for a phylogenetic reconstruction of tumour evolution, which when integrated with 
clinical, pathological and radiological data provide for a detailed understanding of 
disease progression, with initial treatment driving tumour dissemination along four 
distinct trajectories. Infiltration of distant sites was associated with a later genome 
doubling, whilst there was evidence of convergent evolution of different lesions 
acquiring distinct alterations targeting NF-κB. These data represent an unusual 
opportunity to understand the evolutionary history of a highly recurrent childhood 
brain tumour, and provide novel therapeutic targets for astroblastoma / CNS HGNET-
MN1. 
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INTRODUCTION 
Astroblastomas are rare glial tumours of unknown origin 1. These lesions are 
characterised by the presence of the perivascular pseudorosettes composed of 
tumour cells with a prominent process extending to a central blood vessel and 
perivascular hyalinization. In the previous (2007) WHO classification no formal grade 
was recommended 2, although well-differentiated and malignant variants have been 
recognized 3, possibly with clinical consequences 4. Astroblastomas are positive for 
GFAP (glial fibrillary acidic protein), S100 and vimentin by immunohistochemistry and 
frequently display focal expression of EMA (epithelial membrane antigen) 4. They 
predominantly occur supratentorially with differential diagnoses including high grade 
glioma, ependymoma, AT/RT (atypical teratoid / rhabdoid tumour) and CNS-PNET 
(primitive neuroectodermal tumour) 1. These lesions most commonly present in 
children and young adults, with a clear female predominance 5 and may have a 
better clinical outcome than glioblastoma 6. Astroblastomas have mostly been 
described in case reports, and their status as a distinct clinicopathological entity has 
been controversial.  
 
In the last few years, large-scale molecular profiling studies of multiple childhood 
brain tumour types has revealed novel insights into the taxonomy of cancers 
occurring within the CNS 7. Specifically, CNS-PNETs have recently been resolved by 
biological subclassification using 450k methylation arrays into either multiple well-
known brain tumour pathologies or one of four new molecular entities 8. These novel 
entities differ in their anatomical location, age at incidence and histological features, 
and are marked by distinct pathognomonic structural variants, and are described as 
CNS neuroblastoma with FOXR2 activation (CNS NB-FOXR2), CNS Ewing sarcoma 
family tumour with CIC alteration (CNS EFT-CIC), CNS high-grade neuroepithelial 
tumour with BCOR alteration (CNS HGNET-BCOR), and CNS high-grade 
neuroepithelial tumour with MN1 alteration (CNS HGNET-MN1). This latter group 
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was specifically associated with gene fusions involving MN1 (22q12.3), usually with 
BEND2 (Xp22.13), but also the alternative partner CXXC5 (5q31.2), and contained 
16/23 cases diagnosed as astroblastoma by the originating centres.  
 
One of the samples in the study described above included a case of astroblastoma 
diagnosed in a 6 year-old girl who suffered ten recurrences of her tumour over a ten-
year period before finally succumbing to her disease. Multiple recurrences have been 
reported previously in isolated cases of astroblastomas with specific high grade 
histological features 9, although the rarity of the disease and lack of available tissue 
has precluded biological analyses of this phenomenon. We were fortunate to have 
access to tumour tissue from all 11 surgical interventions from this patient for exome 
sequencing, which has allowed us the unique opportunity to study the clonal 
evolution of this novel molecular entity over a long period in the childhood setting, 
and in response to different treatment strategies.  
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MATERIALS and METHODS 
Case and samples 
All patient material was collected after informed consent and subject to the Children's 
Health Queensland Human Research Ethics Committee local research ethics 
committee approval, and all procedures performed in accordance with relevant 
guidelines and regulations. Formalin-fixed paraffin-embedded (FFPE) tumours 
samples were available for all 11 resections (termed A-I) with frozen tumour 
available for 4 of these (E, F, H and I). Detailed histopathological assessment was 
carried out on haematoxylin and eosin stained sections. Pre-gadolinium sagittal and 
axial T1, axial T2 FLAIR and diffusion weighted scans of the whole brain were 
performed with post gadolinium coronal and axial T1 weighted scans also acquired.  
 
Immunohistochemistry 
Standard 4µm formalin fixed paraffin embedded histologic sections of tumour were 
stained with the antibodies, EMA clone E29 at 1:100 (Dako Agilent, Santa Clara, CA, 
USA), GFAP polyclonal at 1:1000 (Dako Agilent, Santa Clara, CA, USA), and S100 
polyclonal at 1:2000, (Dako Agilent, Santa Clara, CA, USA), using a Leica Bond III 
(Leica Biosystems) automated immunohistochemical stainer. Staining for NF-κB p65 
D14E12 (Cell Signalling, The Netherlands) was undertaken on a Leica Bond Max 
automated immunohistochemical stainer with protocol F, at an antibody 
concentration of 1:500, after heat induced epitope retrieval at pH 6 for 20 minutes. 
 
 
DNA extraction and sequencing 
At least 400ng DNA was sent for exome sequencing at the Tumour Profiling Unit, 
ICR, London, UK using the 50Mb Agilent SureSelect platform (Agilent, Santa Clara, 
CA, USA), and paired-end-sequenced on an Illumina HiSeq2000 (Illumina, San 
Diego, CA, USA) with a 100bp read length. Reads were aligned to the hg19 build of 
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the human genome using bwa v 0.7.5a (bio-bwa.sourceforge.net), and PCR 
duplicates removed with PicardTools 1.5 (pcard.sourceforge.net). Somatic single 
nucleotide variants were called using the Genome Analysis Tool Kit v3.3-0 based 
upon current Best Practices using local re-alignment around indels, downsampling 
and base recalibration with variants called by the Unified Genotyper 
(broadinstitute.org/gatk). Variants were annotated using the Ensembl Variant Effect 
Predictor v71 (ensembl.org/info/docs/variation/vep) incorporating SIFT (sift.jcvi.org) 
and PolyPhen (genetics.bwh.harvard.edu/pph2) predictions, COSMIC v64 
(sanger.ac.uk/genetics/CGP/cosmic) and dbSNP build 137 
(ncbi.nlm.nih.gov/sites/SNP) annotations. Copy number was obtained by calculating 
log2 ratios of tumour/normal coverage binned into exons of known genes, smoothed 
using circular binary segmentation (bioconductor.org) and processed using in-house 
scripts. We also determined the somatic allele-specific copy number profiles using 
read depth from whole genome / exome sequencing as above analysed by ASCAT 
10, which also provided for an estimate of the non-neoplastic cell contamination of the 
sample as well as the overall ploidy of the tumour. Loss of heterozygosity (LOH) was 
also calculated using ASCAT based upon a minor allele frequency <0.2. Allele-
specific copy number, LOH and tumour cell purity were then used to calculate the 
cancer cell fraction (CCF) which estimates the percentage of tumour cells carrying 
each mutation 11, and truncated to 100% where experimental variability in sequence 
reads produced a value greater than this figure. Intratumoral heterogeneity and the 
number and frequency of sub-populations within individual tumour samples were 
calculated with the EXPANDS algorithm using evolutionary biology principles 
including the Shannon and Simpson indices, and allowing for the concept that 
subclones may share a subset of variants that may be nested within each other 12. All 
data are deposited in the European Genome-phenome Archive (ebi.ac.uk/ega) under 
accession number EGAS00001002432.  
 
 7 
RNA extraction and sequencing  
RNA was extracted from frozen tumour tissue following the RNeasy Plus Mini Kit 
protocol (Qiagen), quantified on a 2100 Bioanalyzer (Agilent Technologies), and 
sequenced on an Illumina GA-II genome analyser as 100bp paired end reads. RNA 
sequences were aligned to hg19 and organised into de-novo spliced alignments 
using bowtie2 and TopHat2 (https://ccb.jhu.edu/software/tophat).  Raw read counts 
and fragments per kilobase per million reads mapped (FPKPM) were calculated for 
all known Ensembl genes in assembly v74 using bedtools 
(bedtools.readthedocs.org) and Cufflinks (cole-trapnell-lab.github.io/cufflinks/). 
Putative fusions were identified using Chimerascan 0.4.5 
(code.google.com/archive/p/chimerascan/). Published RNAseq data was taken from 
Mackay et al.13, whilst published Affymetrix gene expression array data was taken 
from Sturm et al.8   
 
MN1:BEND2 RT-PCR 
Total RNA was extracted frozen samples using the Qiagen RNeasy Plus Mini Kit. 
cDNA was synthesized using the SuperScript II system (Life Technologies) 
according to manufacturer’s protocol. Four PCR primers (Life Technologies) were 
designed using Primer3, ±200bp from the breakpoints to generate amplicons 
spanning the breakpoint-junction-sequences of the predicted fusion. The following 
primers were used: MN1 Fwd1 - CAGCAGTTCAGCATCTCCGA, BEND2 Rev1 - 
TTGTACGGCCAGCAAATGGA, MN1 Fwd2- CATTGACCTGGACTCGCTGA, 
BEND2 Rev2 - TGACGCTGTTTTCCGTGTTG. cDNA from KNS42 was used as 
control. PCR was carried out with Platinum Taq DNA Polymerase High Fidelity (Life 
Technologies) in a 25μl volume using a 2-Step-Touchdown programme: (94°C 30 
sec, 68°C 45 sec, 72°C 1 min, 18 cycles; 94°C 30 sec, 50°C 45 sec, 72°C 1 min, 30 
cycles), and cleaned up with the IllustraTM ExoStarTM 1-STEP kit (VWR). Sanger 
DNA sequencing of the PCR products was performed by DNA Sequencing & 
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Services (MRCPPU, College of Life Sciences, University of Dundee, Scotland, 
dnaseq.co.uk) using Applied Biosystems Big-Dye Ver 3.1 chemistry on an Applied 
Biosystems model 3730 automated capillary DNA sequencer. 
 
MN1:BEND2 FISH 
BAC clones were purchased from BACPAC Resources Center (Children's Hospital 
Oakland Research Institute, Oakland, CA, USA) and FISH-mapped onto metaphase 
slides to ensure specificity. BACs used were: MN1 (FITC / DIG) - RP11-145O03, 
RP11-166A15; BEND2 (Spectrum Orange / biotin) - RP11-768A24, RP11-46N14. 
BAC DNA was amplified from 10ng starting material using the IllustraTM GenomiPhi 
V2 DNA amplification kit (GE Healthcare) according to the manufacturer’s 
instructions. Probes were labelled with either biotin or DIG using the BioPrime DNA 
Labelling System (Life Technologies). Tissue slides were stripped of paraffin using 
xylene, pre-treated with 0.2M HCL and 8% sodium thiocyanate for 30 minutes or 
Spot-light pre-treatment buffer (Life Technologies) at 80˚C for 1hr, digested in 
0.025% pepsin (Sigma) in 0.01M HCL at 37˚C for 20 – 70 minutes or twice in Digest-
All pepsin solution (Life Technologies) for 21 minutes before adding a prepared 
probe mix with (75%) hybridization buffer under a coverslip and denatured for 5 
minutes at 80˚C on a heat block.  They were then incubated overnight in a humidified 
chamber at 37˚C, mounted in Vectashield with DAPI (Vector Laboratories, 
Peterborough, UK), and captured on the Metafer Scanning and Imaging platform 
(MetaSystems, Altlussheim, Germany) at x60 using filters for DAPI, Cy3 and FITC. 
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RESULTS  
Initial presentation 
A six-year old girl presented with recurring headaches, and upon magnetic 
resonance imaging (MRI) a cystic and solid mass within the superior aspect of the 
left parietal lobe anterior to the central sulcus was observed (Specimen A). After 
surgical resection, histological examination revealed an unusual tumour with solid, 
solid papillary and papillary histological growth patterns. Tumour cells were radially 
orientated around often hyalinised vascular walls, forming perivascular pseudo-
rosettes. There was focal necrosis and numerous mitoses (up to 28 per 10 high 
power fields). The tumour cells were positive for vimentin and exhibited patchy 
positive staining for GFAP and S-100, as well as focal positivity for EMA (Figure 1). 
Sections were negative for SMA, MSA, desmin, myogenin, myoglobin, neurofilament 
protein and cytokeratin 34 Beta E12 (not shown). Conventional cytogenetics 
identified loss of an X chromosome and partial deletion of 22q. Differential diagnoses 
included high grade glioma, anaplastic ependymoma and rhabdoid papillary 
meningioma, but the pathologic features were thought to be most consistent with an 
astroblastoma with malignant features. No adjuvant chemotherapy was administered 
after gross total resection.  
 
Recurrences  
Over the course of the next 10 years, the patient underwent a further 10 invasive 
procedures to remove a highly recurrent tumour (Figure 2). She was treated with 
chemoradiotherapy with temozolomide after the second surgery at age 7.33 years 
(B), and combined CCNU/temozolomide after a third surgery at age 9.11 years (C). 
Subsequent to this, later recurrences were removed without further radio- or 
chemotherapy. A representative T1 weighted axial MRI series for all 11 lesions and a 
final progression image is provided (Figure 3). The anatomical locations ranged from 
the left frontal/fronto-parietal lobes (A-E), parietal parafalcine region (F), temporal 
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lobe (G, I), sphenoid region (H) and nasal cavity (J, K). The histology for all samples 
were consistent with that of recurrent anaplastic astroblastoma, with a varying 
degree of atypical mitoses, pseudorosettes, hyalinised vessels and necrosis (Figure 
4). An exception is the seventh surgery (G) which was the most pleomorphic of the 
samples, and appeared upon radiological review to be an entirely separate lesion 
away from the site of the primary tumour and considered to represent a local 
metastasis. The patient died aged 16.42 years. 
 
Identification of MN1:BEND2 fusion 
FFPE material was available for all 11 specimens, with three tumours having 
sufficient frozen sample (F, H, I), providing material for RNA sequencing. Analysis for 
fusion transcripts in these latter samples showed a consistent apparent inter-
chromosomal translocation between MN1 (meningioma disrupted in balanced 
translocation 1, 22q12.1) and BEND2 (BEN domain  containing 2, Xp22.13) (Figure 
5A). This structural variation involves a deletion at chromosome 22q and breakpoints 
in intron 1 of MN1 and intron 8 of BEND2, rearrangement, and results in an 
expressed transcript comprising exon 1 of MN1 and exons 9 though 14 of BEND2. 
This was validated in the frozen samples by RT-PCR (Figure 5B), and the FFPE 
specimens by custom FISH probes (Figure 5C) (Supplementary Figure S1). The 
consequence of this fusion is increased expression of BEND2, as seen by exon-level 
sequence coverage by RNA sequencing (Figure 5D).  
 
Tumour evolution  
Exome sequencing was carried out on all surgical specimens (Supplementary Figure 
S2). A total of 110 somatic single nucleotide variants (SNVs) and InDels were found 
in any one or more of the samples (4-36 per specimen, median=13). The highest 
number were found in resection G (n=36). Calculating the cancer cell fractions 
(CCFs) for the somatic variants allowed for a temperospatial reconstruction of the 
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tumour phylogeny based upon common, shared and private events (Figure 6A). 
Aside from the MN1:BEND2 fusion, only a single common mutation was observed in 
all specimens – a small deletion (p.1211delQ) in GIGYF2 (GRB10 interacting GYF 
protein 2).  
 
The interpretation of multi-sample sequencing data can be heavily influenced by the 
extent of intratumoral heterogeneity present across the tumour(s). To assess this, we 
investigated the subclonal architecture of each specimen using EXPANDS (Figure 
6B). The number of major subclones ranged from 4-10, with the exception of 
specimen J, which appeared to be largely clonal, and notably distinct from the multi-
clonal specimen K. Strikingly different compositions from the initial presentation were 
also observed in the spatially distinct specimens D (a considerably more complex 
subclonal architecture compared to A, B and C) and G (dominated by a predominant 
clone) (Figure 6B).   
 
Upon phylogenetic reconstruction, the samples were split in two main branches 
(Figure 6C). The first included the primary presentation within the frontal lobe (A) and 
the closely-related local recurrences B and C. These were found to have few 
chromosomal alterations and 8-10 somatic SNVs/InDels. Specimen D, resected from 
the fronto-parietal region, was distinguished by several additional alterations 
including missense variants in the paracaspase MALT1 and acquisition of gain of 
chromosome 13q. Notably, the other samples in this branch were from the latest 
surgeries acquired from the nasal cavity (J and K), which shared the relatively stable 
copy number genome and few mutations, though K had acquired several additional 
variants including the BCL2-associated transcription factor BCLAF1.  
 
The remaining samples were found on a second major branch (Figure 6C). Sample 
G formed a branch separate from the other resections, reflecting its distinct 
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radiopathological features, location within the temporal lobe, and with few 
chromosomal changes but a large number of private mutations including missense 
mutations in the serine/threonine kinase MAP3K1 and lysine demethylase KDM5A. 
The other four samples were associated with the acquisition of a large number of 
DNA copy number changes, particularly whole chromosomal arm gains, as well as 
mutation in LRRC4. Two specimens resected from the parafalcine region (E) and the 
vertex superior to the frontal lobe (F) formed their own sub-branch, the former 
acquiring a truncating mutation in the meiotic recombination protein REC8, the latter 
a missense variant in MAP3K7. Finally, a further sub-branch was found to contain 
the remaining tumours H and I, resected from the sphenoid region and temporal 
lobe, respectively.  
 
The concordance of these distinct sub-branches having apparently independently 
acquired mutations in genes associated with NF-κB signalling (MALT1, BCLAF1, 
MAP3K1, LRRC4 and MAP3K7) prompted us to investigate pathway activation by 
immunohistochemistry for RELA-p65 (Figure 7). Whilst only very weak staining was 
observed in specimens A, B and C (absent these mutations), all other tumours 
showed strong nuclear-cytoplasmic accumulation of staining indicative of NF-κB 
signalling. This was associated with the increased expression of the target gene IL8 
in specimens for which RNAseq data was available, compared to a series of 
hemispheric high grade glioma (HGG) samples (Supplementary Figure S3A). In an 
independent series of brain tumour samples, IL8 gene expression was found to be at 
equivalent levels to C11orf95-RELA fusion-positive ependymoma, and significantly 
elevated compared to AT/RT, HGG and medulloblastoma. 
 
Interpreting the molecular and clinical data together, we propose an evolutionary 
history whereby after acquisition of the primary driving MN1:BEND2 fusion (A), there 
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was an early spread of tumour cells from the original site after initial 
chemoradiotherapy and surgery, with divergence along several pathways (Figure 8). 
The first involved little genomic instability, with local recurrence in the frontal lobes 
(B, C) and an evolutionarily independent spread to parietal regions (D), followed >5 
years later by eventual migration such that the latest surgical interventions were in 
the nasal cavity (J, K). These latter two samples had remarkably different subclonal 
compositions, suggestive of distinct temporal origins. In parallel were three 
metastatic routes involving distinct anatomical regions. The first appears to be an 
early escape to the temporal lobe (G), with few overlapping somatic alterations with 
the primary tumour, and predominantly clonal. The latter two seem to occur after the 
acquisition of major chromosomal changes reminiscent of genome doubling, and 
diverged along either superior (E, F) or inferior (H, I) paths over the course of 18 
months.  
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DISCUSSION 
Since it’s first description by Bailey and Cushing in 1924 14, there has been 
controversy as to whether the histopathological features which are suggestive of the 
term astroblastoma mark a distinct entity 2. There have historically been few 
biological studies of astroblastoma, which has made resolution of its pathogenesis 
difficult. The largest study, from Brat and co-workers in 2000, carried out DNA copy 
number profiling by comparative genomic hybridization (CGH) on 7 cases, and 
reported frequent gains of chromosome 19 and 20q, as well as losses of 9q, 10 and 
X 15. Prior to this, karyotyping of a case from a 15 year old girl revealed monosomies 
of chromosomes 10, 21 and 22 16. More recently, a lack of IDH1 17 and TP53 18 
mutations in astroblastomas has been noted but there have been no characteristic 
genetic features reported giving positive clues as to their likely origin 19.  
 
Recent integrated molecular analysis of another childhood brain tumour with 
controversial claims to being a disinct entity, CNS-PNET, have helped to clarify these 
issues, with the identification of a novel molecular entity, CNS HGNET-MN1, in which 
16/41 cases were initially diagnosed as astroblastoma. This group of tumours had 
the oldest age at diagnosis, a largely supratentorial location, a striking female:male 
predominance, and the best overall survival of all novel entities described 8. 
Histologically they had features overlapping with that descibing astroblastoma (e.g. 
dense perivascular hyalinization) but not all cases could be so rationalised. They 
expressed GFAP but lacked neuronal antigen expression.  
 
The most striking feature of the newly described CNS HGNET-MN1 group were the 
pathognomonic fusions of MN1 (and BEND2, or in one case, CXXC5) 8. The highly 
recurrent case described in the present paper harboured the most common fusion, 
MN1:BEND2, resulting in expresson of a transcript containing the large exon 1 of 
MN1 with exons 9-14 of the longest transcript of BEND2. This was seen in all 11 
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surgical resection samples in our case, indicating an early, clonal, drive event in the 
pathogenesis of this tumour. Althought the function of BEND2 is unknown, a 
consequence of the mutation is the high expression levels of the two BEN-domains 
encoded by the gene, thought to play a role in chromatin organisation 20 and neural 
transcriptional regulation 21. As other fusion partners of MN1 have been reported 8, 
disruption of this gene may instead be the pathogenic event. MN1 is frequently 
targeted by a balanced t(4,22) translocation certain subtypes of meningioma, and 
acts as a transcriptional co-regulator of retinoic acid-mediated gene expression along 
with p300 22, 23. 
 
Although generally considered to harbour a good prognosis, extensively recurrent 
cases have been previously reported 9. Exome sequencing of the multiple 
recurrences which occurred in the patient presented here afforded us the opportunity 
to infer a molecular evolution of the disease which aligned with the clinical 
presentation. This involved an early divergence from the original site after initial 
treatment, disseminating via four distinct anatomical routes to multiple locations 
within the brain. At a relatively advanced stage of presentation, this involved a 
doubling of the tumour genome not seen in the initial local recurrences. Interestingly, 
the final biopsies obtained via the nasal cavity were found not to contain these 
chromosomal changes, and were rather two further independent infiltrative 
extensions of the original local recurrence-derived branch.  
 
In all but the very earliest of the surgical samples we analysed, in addition to the 
truncal MN1:BEND2 fusion we identified variants in genes associated with NF-κB 
signalling, and concurrent pathway activation as evidenced by immunohistochemistry 
for RELA-p65. These included MAP3K1, a downstream target of Bcr-Abl reported to 
mediate the anti-apoptotic effects of NF-κB 24; MAP3K7, which phosphorylates the 
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IKK complex, leading to eventual release of inhibition and activation of NF-κB 25; 
MALT1, which has both scaffolding functions and proteolytic activity essential for NF-
κB activation 26; BCLAF1, a direct target of p65 and c-Rel, and essential for C/EBPβ 
upregulation 27; and LRRC4, a candidate tumour suppressor gene down-regulated in 
gliomas which appears to play a role in cellular proliferation by mediating MAPK/PI3K 
and NF-κB signalling 28. NF-κB has long been thought to play a role in glioma 
phenotypes 29, and more recently emerged as a critical regulator in ependymoma 30. 
The observation that these mutations occurred in the later specimens suggests a 
possible role in progression of CNS HGNET-MN1 tumours, and also provides a 
plausible therapeutic target. 
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LEGENDS FOR FIGURES 
Figure 1 – Histopathological features at presentation. Sample A: with haematoxyllin 
and eosin (H&E) staining, there are areas of multiple perivascular pseudorosettes 
(inset) as well as areas of necrosis and vascular hyalinisation. Cells are 
heterogenously positive for EMA, GFAP and S100 by immunohistochemistry. 
Original magnification x100 (inset, x400).  
 
Figure 2 – Clinical timeline. Surgical samples are lablled A-K,  and annoated by age 
at resection/biopsy and anatomical location. Points of treatment initiation are 
indicated in red. RT, radiotherapy; TMZ, temozolomide; CCNU, lomustine. 
 
Figure 3 – Post-contrast, T1 weighted axial MRI images of all recurrences. A-K, 
representative images prior to 1st to 11th surgical resections respectively. L, 
representative image of final tumour progression. A: age 6.79, underwent surgical 
resection of left frontal tumour. B: age 7.33, left frontal craniotomy, partial resection, 
treated with radiotherapy and temozolomide. C: age 9.11, left frontal subtotal 
resection, treated with CCNU and temozolomide. D: age 11.26, biopsy. E: age 13.10, 
resection. F: age 14.04, resection. G: age 14.29, right temporal craniotomy, gross 
total resection. H: age 14.67, sphenoid tumour, endoscopic endonasal 
sphenoidectomy. I: age 14.96, left temporal resection. J: age 16.05, nasal biopsy. K: 
age 16.17, nasal cavity resection. The patient died aged 16.42 years (Final). 
 
Figure 4 – Histopathological features of all recurrences. A: Initial presentation – age 
6.79 years (as in Figure 1). B: Similar morphology with high focal mitotic activity, 
fewer perivascular pseudorosettes and sharply demarcated borders. Evidence of 
calcification C: More cellular tumour with only single ribbon-like structures and almost 
no pseudorosettes seen. D: Similar morphology to C, with hyalinised vessels. E: 
Fewer mitotic figures present, and cells seen with conspicuous nucleoli. F: Similar to 
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B, but with no calcification. Increased perivascular ribbons and necrotic foci. G: 
Distinct lesion with prominent cellular pleomorphism and large hyperchromatic nuclei. 
Many cells have an epithelioid appearance. There are papillary structures and 
numerous pseudorosettes. H: Tumour is infiltrating the sphenoid bone and sinus and 
has numerous invasive, pleomorphic cells with hyperchromatic and large nuclei. I: 
Well vascularised pleomorphic tumour with several pseudorosettes. J: Tumour was 
mostly necrotic tumour but viable tissue. showed pseudorosettes around hyalinised 
vessels. K: Tumour was mostly necrotic. but preserved tumour shows numerous 
pseudorosettes, mostly around hyalinised vessels with thick walls. Original 
magnification x200. 
 
Figure 5 – Identification of MN1:BEND2 fusion. (A) Cartoon of fusion between exon 
1 of MN1 (22q12.1, orange) and exons 9-14 of BEND2 (Xp22.13, blue), with 
spanning reads from RNAseq from sample F underneath. (B) Top: RT-PCR using 
primers designed against MN1, BEND2, and spanning the breakpoint, in samples E, 
F and H. KNS42 paediatric glioblastoma cells were used as a fusion-negative 
control. Beta actin (ACTB) was used as a positive RT-PCR control. Bottom: Sanger 
sequencing of the fusion band in sample E, showing a sequence spanning the 
breakpoint. (C) FISH using probes directed against MN1 (green) and BEND2 (red), 
detecting fusion signals throughout sample H. (D) RNAseq coverage of BEND2, with 
high levels of expression of exons 9-14 in sample E.  
 
Figure 6 – Intratumoral heterogeneity and phylogentic reconstruction. (A) 
Contingency plots for cancer cell fractions (CCF) of somatic mutations identified in 
specimens A-K. Key as provided in the figure. (B)  Coxcomb plots for number of 
subclones in each specimen, with the area of each scaled according to the number 
of variants predicted to be contained within, as calculated by EXPANDS. They are 
placed along concentric circles according to the sampling time after initial diagnosis, 
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and in distinct anatomical locations. (C) Phylogenetic tree of tumour specimens built 
using maximum parsimony from exome sequencing data. Blue line represents the 
‘trunk’, yellow lines the shared major and minor ‘branches’, red lines the private 
‘leaves’. Selected alterations are labelled, those targeting the NF-κB pathway are 
shaded.  
 
Figure 7 – NF-κB pathway activation. Strong cytoplasmic and nuclear expression of 
RELA/NF-κB-p65 by immunohistochemistry is seen in all later specimens (D-K), and 
only weakly observed in A-C. Main image, original magnification x200; inset x400 
 
Figure 8 - Integrated clinical and molecular inference of tumour evolution. Taking all 
available data, we proposed an evolutionary history along four distinct trajectories 
over 10 years.  Brain diagram modified from Patrick J. Lynch, medical illustrator; C. 
Carl Jaffe, MD, cardiologist, under Creative Commons Attribution 2.5 License 2006. 
(https://upload.wikimedia.org/wikipedia/commons/4/44/Brain_human_lateral_view.svg) 
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